.jpg)
.png)
TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
???? Are You a Music Artist Ready to Be Heard? ????
It’s time to stop playing around and get your music on real radio. Join a platform that truly supports artists and gives you the exposure you deserve.
SugarWaterRadio is changing the game—one song at a time.
Get real airplay, real listeners, and real results.
???? Submit your music now at SugarWaterRadio.com
Let’s make your dream a reality.
CLICK HERE & TURN UP YOUR FUTURE! ????
Copyright © 2023 swsports. All Rights Reserved
